$BCLI bottom Pr $3.87

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
$BCLI bottom Pr $3.87


Website

NEW YORK and PETACH TIKVAH, Israel , Oct. 7, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). NurOwn™ consists of autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors, and is currently being studied in a randomized, double-blind, placebo-controlled phase 2 clinical trial in ALS patients.

"We are pleased that the FDA has granted Fast Track status for NurOwn™ as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino , MD, PhD, Chief Executive Officer of BrainStorm. "We expect Fast Track designation, which recognizes the potential of NurOwn™ as to address an unmet medical need in ALS, to help speed and improve our development program."

The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious conditions and demonstrate the potential to address unmet medical needs. Under the FDA Modernization Act of 1997, the Fast Track program provides for increased meetings with and written communications from the FDA, and allows for the submission of an NDA on a rolling basis. For more information, see http://www.fda.gov/ForPatients/Approvals/Fast/ucm405399.htm .

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University . NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel , and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

Shares Outstanding: 15.16M
Float: 11.34M




Headlines

Tuesday, October 7, 2014
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALSPR Newswire

Monday, October 6, 2014
BrainStorm Reports Last Patient Visit in Phase 2a ALS StudyPR Newswire

Friday, October 3, 2014
BRAINSTORM CELL THERAPEUTICS INC. FinancialsEDGAR Online Financials

Tuesday, September 30, 2014
BrainStorm Completes Uplisting to the NASDAQ Capital MarketMarketwired

Tuesday, September 16, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, AmendmentsEDGAR Online
BrainStorm Announces Completion of Reverse Split of Common Stock, a Key Step for Uplisting on the NASDAQAccesswire
Tuesday, September 9, 2014
BrainStorm Provides Update on NASDAQ Uplisting ProcessMarketwired

Thursday, September 4, 2014
BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment ConferenceAccesswire

Wednesday, September 3, 2014
BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS DiseasesAccesswire

Monday, August 18, 2014
FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm’s Phase 2 ALS TrialAccesswire

Wednesday, August 13, 2014
BCLI: Brainstorm Moves Into Phase 2 ALS TrialZacks Small Cap Research

Wednesday, July 30, 2014
Coverage initiated on Brainstorm Cell Therapeutics by Maxim GroupBriefing.com

Monday, July 28, 2014
BrainStorm Receives Notice of Allowance on US PatentAccesswire

Tuesday, July 15, 2014
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical TrialAccesswire

Friday, July 11, 2014
BrainStorm Announces Publication of Preclinical Multidose Study of NurOwnMarketwired

Friday, June 27, 2014
BrainStorm Cell, Octane construct bioreactor prototype for NurOwntheflyonthewall.com
BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem CellsMarketwired

Tuesday, June 24, 2014
Brainstorm Cell Therapeutics, Inc.: A Small Biotech With Big Plans And Huge Potentialat Seeking Alpha

Friday, June 13, 2014
BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement FinancingMarketwired

Thursday, June 12, 2014
BrainStorm Tackles Neurodegenerative Diseases With Novel Cell Therapyat Seeking Alpha



Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 236

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 564

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 517

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 81

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 309

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 642

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 113

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 281

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 710

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 453

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading

Top 5 Most Recently Viewed Articles

Toncoin's Recent Surge: A Detailed Overview of Market Trends

Updated Category News Views 119

Toncoin Experiences a 7.55% Price Surge Recently, Toncoin (TON/USD) saw a significant price increase of 7.55% within just 24 hours, elevating its value to $5.09. This rise comes after a slight decline of 1.0% over the past week, where the price dipped from $5.16. It's worth noting that Toncoin's all-time high is an impressive $8.25. Insights into Toncoin's Trading Volume...

Continue Reading
Royal Unibrew's Share Buy-Back Program Update and Insights

Updated Category News Views 199

Overview of Royal Unibrew's Share Buy-Back Program Royal Unibrew has embarked on a strategic initiative by initiating a share buy-back program as part of its efforts to optimize shareholder value. This program was officially launched on February 25 and is set to run until August 15, with a budget cap of DKK 250 million. Understanding the Regulatory Framework This share...

Continue Reading
RiskSpan Unveils Groundbreaking AI Solution for MBS Insights

Updated Category News Views 208

Revolutionizing MBS Data Analysis with AI RiskSpan recently introduced Agentic AI for MBS Data, a cutting-edge tool designed to transform the way mortgage-backed securities (MBS) professionals analyze data. With this innovative technology, users can access immediate, sourced, and context-rich insights effortlessly. Gone are the days when analysts needed to decode complex...

Continue Reading
Embark on Your Filmmaking Journey with a Unique MFA Program

Updated Category News Views 180

Discover the Future of Filmmaking Education The Palm Beach Photographic Centre has recently introduced an innovative graduate film school, distinctively designed to revolutionize how advanced filmmaking is taught. This program emphasizes a hands-on approach, providing participants with the unique opportunity to create a feature film while earning their Master of Fine Arts...

Continue Reading
Evaluating STMicroelectronics' Market Performance and Future

Updated Category News Views 133

An Overview of STMicroelectronics' Current Market Position STMicroelectronics Inc. (NYSE: STM) has recently experienced a surge in its share price, currently trading at $27.86 after a notable increase of 2.58%. This surge is a welcome sign for investors as the stock has also appreciated by 8.67% over the past month. However, a year-on-year analysis shows a decline of...

Continue Reading